AR and prostate carcinoma: Interestingly, AR-negative PC3 and NEPC-like LSCPC01 cell lines were significantly sensitive to ceritinib compared with normal prostate epithelial cells or AR-positive cancer cells, whereas LY2033298 and PD102807 had no effect on prostate cancer cells (Fig. 7A–C).